Harbor Investment Advisory’s Ultragenyx Pharmaceutical RARE Stock Holding History

Harbor Investment Advisory’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.3K	Buy	+1,566	New	+$38.9K	﹤0.01%	747
2023 Q2	–	Sell	-659	Closed	-$26.4K	–	1372
2023 Q1	$26.4K	Sell	659 -214	-25%	-$9.18K	﹤0.01%	857
2022 Q4	$40.4K	Hold	873	–	–	0.01%	744
2022 Q3	$36K	Hold	873	–	–	0.01%	776
2022 Q2	$52K	Buy	873 +118	+16%	+$7.26K	0.01%	696
2022 Q1	$55K	Hold	755	–	–	0.01%	726
2021 Q4	$63K	Hold	755	–	–	0.01%	673
2021 Q3	$68K	Hold	755	–	–	0.01%	639
2021 Q2	$72K	Sell	755 -75	-9%	-$7.81K	0.01%	595
2021 Q1	$95K	Sell	830 -73	-8%	-$9.94K	0.01%	494
2020 Q4	$125K	Buy	903 +153	+20%	+$18.1K	0.02%	404
2020 Q3	$62K	Buy	750 +308	+70%	+$25.5K	0.01%	451
2020 Q2	$35K	Hold	442	–	–	0.01%	512
2020 Q1	$20K	Buy	+442	New	+$22.9K	0.01%	580

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Harbor Investment Advisory's RARE Position: Q2 2026 in Review

Harbor Investment Advisory opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 1,566 shares worth $52.3K. The stake represents ﹤0.01% of the portfolio and ranks #747 among its holdings. This is a return to the name: Harbor Investment Advisory previously reported a position in RARE as recently as Q1 2023.

Harbor Investment Advisory first reported a position in RARE in Q1 2020 and has held it in 14 quarters since. The position peaked at $125K in Q4 2020. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Harbor Investment Advisory held 1,566 shares of Ultragenyx Pharmaceutical worth $52.3K as of Q2 2026.
Ultragenyx Pharmaceutical was a new Harbor Investment Advisory position in Q2 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of Harbor Investment Advisory's portfolio in Q2 2026, its #747 holding.
Harbor Investment Advisory first reported a position in Ultragenyx Pharmaceutical in Q1 2020 and has held it in 14 quarters since.
Harbor Investment Advisory's Ultragenyx Pharmaceutical position peaked at $125K in Q4 2020.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Harbor Investment Advisory's 13F filing for Q2 2026, filed 7 Jul 2026.